Jefferies Maintains Buy on Boston Scientific, Lowers Price Target to $100

Benzinga Newsdesk www.benzinga.com Negative 56.7%

Neg 56.7% Neu 0% Pos 0%

Jefferies analyst Matthew Taylor maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $110 to $100.